Pictet Asset Management Holding SA Has $107.08 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS

Posted by Geri Gentry on Jun 29th, 2026

Pictet Asset Management Holding SA lifted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.2% in the 1st quarter, HoldingsChannel reports. The fund owned 1,434,995 shares of the company’s stock after purchasing an additional 16,504 shares during the period. Pictet Asset Management Holding SA’s holdings in Ionis Pharmaceuticals were worth $107,077,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in IONS. Grandfield & Dodd LLC boosted its stake in Ionis Pharmaceuticals by 0.4% during the 4th quarter. Grandfield & Dodd LLC now owns 37,821 shares of the company’s stock valued at $2,992,000 after purchasing an additional 146 shares during the last quarter. Wedmont Private Capital raised its stake in shares of Ionis Pharmaceuticals by 3.2% in the fourth quarter. Wedmont Private Capital now owns 5,536 shares of the company’s stock worth $460,000 after purchasing an additional 173 shares during the last quarter. Prospera Financial Services Inc raised its stake in shares of Ionis Pharmaceuticals by 3.9% in the fourth quarter. Prospera Financial Services Inc now owns 4,759 shares of the company’s stock worth $376,000 after purchasing an additional 178 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Ionis Pharmaceuticals by 2.6% in the fourth quarter. MetLife Investment Management LLC now owns 9,674 shares of the company’s stock valued at $765,000 after purchasing an additional 246 shares in the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of Ionis Pharmaceuticals by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 48,545 shares of the company’s stock valued at $3,176,000 after purchasing an additional 301 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Key Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

Positive Sentiment: Ionis received FDA approval expanding TRYNGOLZA to treat severe hypertriglyceridemia, strengthening the drug’s commercial opportunity and making it the first approved therapy for the condition. Article Title
Positive Sentiment: Ionis announced a licensing deal with Recordati for ex-U.S. rights to zilganersen in Alexander disease, which provides upfront and royalty potential while allowing Ionis to keep U.S. commercialization rights. Article Title
Positive Sentiment: Leerink Partners raised its price target on Ionis, signaling continued analyst confidence in the company’s pipeline and commercial execution. Article Title
Neutral Sentiment: HC Wainwright kept a Buy rating but lowered some 2027 EPS estimates, which is a mild headwind but not a major shift in the firm’s overall view. Article Title

Ionis Pharmaceuticals Stock Performance

Shares of IONS opened at $81.18 on Monday. The stock has a 50 day moving average of $75.03 and a 200 day moving average of $77.33. The company has a market capitalization of $13.42 billion, a price-to-earnings ratio of -39.22 and a beta of 0.37. Ionis Pharmaceuticals, Inc. has a 12 month low of $39.37 and a 12 month high of $86.74. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 2.75.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.29. The business had revenue of $246.09 million for the quarter, compared to analysts’ expectations of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The business’s revenue was up 86.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.93) earnings per share. As a group, sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.69 earnings per share for the current year.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Brian Birchler sold 973 shares of the business’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $75.04, for a total value of $73,013.92. Following the transaction, the executive vice president directly owned 67,500 shares of the company’s stock, valued at approximately $5,065,200. The trade was a 1.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Brett P. Monia sold 50,000 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $80.59, for a total transaction of $4,029,500.00. Following the transaction, the chief executive officer owned 245,571 shares of the company’s stock, valued at approximately $19,790,566.89. The trade was a 16.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 190,153 shares of company stock worth $14,606,373. 1.81% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Tuesday, April 21st. Raymond James Financial began coverage on Ionis Pharmaceuticals in a research note on Friday, April 10th. They set an “outperform” rating and a $104.00 price objective on the stock. Leerink Partners upped their target price on shares of Ionis Pharmaceuticals from $122.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday. Royal Bank Of Canada upped their target price on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Finally, Needham & Company LLC increased their target price on shares of Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $102.90.

Read Our Latest Report on IONS

Ionis Pharmaceuticals Company Profile

(Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.